Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Shares Gap Up to $23.80

Posted by on Apr 23rd, 2023

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating)’s stock price gapped up prior to trading on Friday . The stock had previously closed at $23.80, but opened at $24.64. Calliditas Therapeutics AB (publ) shares last traded at $24.64, with a volume of 912 shares.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Citigroup lifted their price target on Calliditas Therapeutics AB (publ) from $76.00 to $79.00 and gave the company a “buy” rating in a research note on Friday, February 24th. Guggenheim initiated coverage on Calliditas Therapeutics AB (publ) in a research note on Tuesday, February 28th. They issued a “neutral” rating on the stock. One analyst has rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, Calliditas Therapeutics AB (publ) has an average rating of “Moderate Buy” and an average price target of $79.00.

Calliditas Therapeutics AB (publ) Stock Up 3.4 %

The company has a quick ratio of 4.33, a current ratio of 4.34 and a debt-to-equity ratio of 0.95. The firm has a market cap of $733.23 million, a PE ratio of -15.10 and a beta of 1.55. The stock has a 50-day simple moving average of $21.77 and a two-hundred day simple moving average of $18.72.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT – Get Rating) last issued its earnings results on Thursday, February 23rd. The company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.46. Calliditas Therapeutics AB (publ) had a negative return on equity of 55.18% and a negative net margin of 56.10%. The company had revenue of $40.04 million during the quarter, compared to analysts’ expectations of $18.93 million. Analysts expect that Calliditas Therapeutics AB will post -0.47 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. HBK Sorce Advisory LLC lifted its holdings in Calliditas Therapeutics AB (publ) by 100.0% in the fourth quarter. HBK Sorce Advisory LLC now owns 90,000 shares of the company’s stock valued at $104,000 after acquiring an additional 45,000 shares during the period. Optiver Holding B.V. lifted its position in Calliditas Therapeutics AB (publ) by 1,304.3% in the third quarter. Optiver Holding B.V. now owns 12,625 shares of the company’s stock worth $191,000 after buying an additional 11,726 shares during the last quarter. Jane Street Group LLC lifted its holdings in shares of Calliditas Therapeutics AB (publ) by 7.6% in the 3rd quarter. Jane Street Group LLC now owns 12,491 shares of the company’s stock worth $191,000 after acquiring an additional 886 shares during the last quarter. Finally, Tower Research Capital LLC TRC grew its holdings in Calliditas Therapeutics AB (publ) by 1,270.2% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,357 shares of the company’s stock valued at $51,000 after purchasing an additional 3,112 shares during the last quarter. Hedge funds and other institutional investors own 3.13% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

(Get Rating)

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy.

Featured Stories

Receive News & Ratings for Calliditas Therapeutics AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calliditas Therapeutics AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.